Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pratosartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 18/20 | 0.73 |
| ▸ | AGTR2 | P50052 | 17/20 | 0.73 |
| ▸ | EDNRA | P25101 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683741 | 0.99 | AGTR1 (0.72) | AGTR1AGTR2EDNRA | |
| SCHEMBL683401 | 0.95 | AGTR1 (0.74) | AGTR1AGTR2EDNRA | |
| SCHEMBL683452 | 0.94 | AGTR1 (0.73) | AGTR1AGTR2EDNRA | |
| SCHEMBL7416052 | 0.91 | AGTR1 (0.63) | AGTR1AGTR2EDNRA | |
| SCHEMBL683778 | 0.86 | AGTR1 (0.55) | AGTR1AGTR2EDNRA | |
| SCHEMBL9076746 | 0.86 | AGTR1 (0.68) | AGTR1AGTR2 | |
| SCHEMBL7309330 | 0.86 | AGTR1 (0.55) | AGTR1AGTR2 | |
| SCHEMBL682656 | 0.86 | AGTR1 (0.56) | AGTR1AGTR2 | |
| SCHEMBL93596 | 0.86 | AGTR2 (0.71) | AGTR1AGTR2 | |
| SCHEMBL683779 | 0.85 | AGTR1 (0.55) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2090 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| CN-113056465-B | Tetrahydropyrane (THP) -substituted bicyclic pyrimidinedione compounds | 迈奥卡迪亚公司 | 2025-01-28 | — | — | CN | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| EP-3873904-B1 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2024-07-10 | — | — | EP | claimed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | claimed |
| US-20240173302-A1 | TREATMENT OF INFLAMMATORY DISEASES | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2024-05-30 | — | — | US | claimed |
| US-11931341-B2 | Compositions and methods for the treatment and prevention of muscular dystrophy | UNIVERSITY OF LOWA RESEARCH FOUNDATION (US) | 2024-03-19 | — | — | US | claimed |
| EP-4313024-A1 | TREATMENT OF INFLAMMATORY DISEASES | Dimerix Bioscience Pty Ltd (AU) | 2024-02-07 | — | — | EP | claimed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | claimed |
| WO-2005070463-A2 | COMPOSITIONS COMPRISING (S)-AMLODIPINE MALATE AND AN ANGIOTENSIN RECEPTOR BLOCKER AND METHODS OF THEIR USE | SEPRACOR, INC. (US) | 2005-08-04 | — | — | WO | claimed |
| WO-2005070462-A2 | COMPOSITIONS COMPRISING (S)-AMLODIPINE AND AN ANGIOTENSIN RECEPTOR BLOCKER AND METHODS OF THEIR USE | SEPRACOR, INC. (US) | 2005-08-04 | — | — | WO | claimed |
| US-20050143435-A1 | Pharmaceutical compositions comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-06-30 | — | — | US | claimed |
| EP-1545540-A2 | COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2005039639-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A SELECTIVE I1 IMIDAZOLINE RECEPTOR AGONIST AND AN ANGIOTENSIN II RECEPTOR BLOCKER | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | claimed |
| WO-2005039638-A2 | THERAPEUTIC AGENT FOR HEART FAILURE COMPRISING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A MATRIX METALLOPROTEINASE INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-06 | — | — | WO | claimed |
| WO-2005000217-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2005-01-06 | — | — | WO | claimed |
| WO-2004110375-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004017896-A2 | COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2004-03-04 | — | — | WO | claimed |